Trolox aids coenzyme Q10 in neuroprotection against NMDA induced damage via upregulation of VEGF in rat model of glutamate excitotoxicity

Improved linear growth after routine zinc supplementation in preterm very low birth weight infants

BACKGROUND

This study was designed (1) to compare growth, morbidity and mortality in < 33-week gestational age (GA) (very preterm, VPT) or very low birth weight (BW < 1500 grams, VLBW) infants before (Epoch-1) and after implementing routine enteral zinc (Zn) supplementation (Epoch-2) to meet recommendations, and (2) to assess serum Zn levels and associated variables.

METHODS

Single-center prospective cohort of 826 infants. The primary outcome was the change (Δ) in Z-scores of accurate length (Δlengthz), weight and head circumference from birth to discharge home.

RESULTS

In Epoch-2 vs Epoch-1 Δlengthz adjusted for confounding variables increased by 0.27 [95% confidence interval (CI) 0.13, 0.42, P < 0.001]. However, morbidity and mortality did not change. In Epoch-2 Zn decreased with GA and postnatal age: low ( < 0.74 mcg/mL) levels were observed in 51% infants. Retinopathy of prematurity (ROP) was independently associated with the lowest Zn [adjusted odds ratio 0.042 (CI 0.006, 0.306), area under the curve=0.928].

CONCLUSION

Routine enteral Zn supplementation was independently associated with improved linear growth but did not prevent occurrence of low Zn. ROP was independently associated with the lowest Zn.

IMPLICATIONS

Multicenter studies are needed to assess whether dosage of enteral Zn should be increased and whether Zn could help prevent ROP.

IMPACT

Implementation of routine enteral zinc (Zn) supplementation was associated with improved linear growth from birth to discharge and a more frequent physiologic growth curve in preterm very low birth weight infants. Serum Zn levels decreased with gestational age and with postnatal age. Low serum Zn levels were observed frequently despite routine Zn supplementation as currently recommended, which suggests a need to re-evaluate current enteral zinc supplementation guidelines for this population. Retinopathy of prematurity among infants < 33 weeks' gestation was independently associated with low gestational age, low birthweight, stage of bronchopulmonary dysplasia and the lowest serum Zn level.

Auxiliary effect of trolox on coenzyme Q10 restricts angiogenesis and proliferation of retinoblastoma cells via the ERK/Akt pathway

Reactive oxygen species (ROS) are essential for cancer signalling pathways and tumour maintenance, making ROS targeting a promising anti-cancer strategy. Coenzyme Q10 (CoQ10) has been shown to be effective against various cancers, but its impact on retinoblastoma, alone or with trolox, remains unreported. Cytotoxicity of CoQ10 alone and with trolox was evaluated in normal human retinal pigment epithelium cells (ARPE-19) and Y79 retinoblastoma cells using CCK-8. Flow cytometry was used to assess apoptosis, cell cycle, ROS, and mitochondrial membrane potential (MMP). Anti-angiogenic potential was tested using human umbilical vein endothelial cells (HUVECs) and chick chorioallantoic membrane (CAM) assays. Mechanistic studies were conducted via RT-PCR and western blotting. CoQ10, alone and with trolox, reduced Y79 cell viability, induced apoptosis through excess ROS generation, and decreased MMP significantly. Both treatments caused G2/M phase cell arrest. The CAM assay showed a significant reduction in endothelial cell proliferation, evidenced by fewer number of co-cultured HUVECs when exposed to CoQ10 or CoQ10 with trolox. The combination of CoQ10 and trolox significantly reduced VEGF-A, ERK, and Akt receptor levels, while CoQ10 alone significantly inhibited ERK and Akt phosphorylation. Together, CoQ10 and trolox reduced protein expression of VEGFA. CoQ10 alone and with trolox, induces apoptosis in Y79 retinoblastoma cells by inhibiting the ERK/Akt pathway and downregulating VEGFA. This study is the first to report the in vitro and in-ovo anti-cancer potential of CoQ10 alone or when combined with trolox, on human retinoblastoma Y79 cells.

Optic Nerve Neuroprotection in Glaucoma: A Narrative Review

In recent years, researchers have been interested in neuroprotective therapies as a cutting-edge therapeutic strategy to treat neurodegenerative disorders by shielding the brain system from harmful events. Millions of individuals worldwide suffer from glaucoma, an ocular neurodegenerative disease characterized by gradual excavation of the optic nerve head, retinal axonal damage, and consequent visual loss. The pathology's molecular cause is still mostly unknown, and the current treatments are not able to alter the disease's natural progression. Thus, the modern approach to treating glaucoma consists of prescribing medications with neuroprotective properties, in line with the treatment strategy suggested for other neurodegenerative diseases. For this reason, several naturally derived compounds, including nicotinamide and citicoline, have been studied throughout time to try to improve glaucoma management by exploiting their neuroprotective properties. The purpose of this review is to examine the naturally derived compounds that are currently utilized in clinical practice for neuroprotection in glaucomatous patients based on scientific data, emphasizing these compounds' pivotal mechanism of action as well as their proven therapeutic and neuroprotective benefits.